# Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

> **NCT03913559** · PHASE2 · TERMINATED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 5 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Inotuzumab ozogamicin
- **DRUG:** Methotrexate
- **DRUG:** Hydrocortisone
- **DRUG:** Cytarabine
- **DRUG:** Diphenhydramine
- **DRUG:** Acetaminophen
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT03913559
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-14
- **Primary completion:** 2025-09-15
- **Final completion:** 2025-09-15
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Closed due to slow accrual
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03913559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03913559, "Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-08-08 from https://api.ai-analytics.org/clinical/NCT03913559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*